Clean Air Advantage
Compressed air ranks as the fourth utility in pharmaceutical manufacturing, accounting for a large share of operating expenses and demanding absolute purity. Electricity makes up more than 80% of a compressor’s life‑cycle cost, driving firms to seek energy‑efficient solutions. Variable‑speed‑drive (VSD) compressors can slash power use by up to 50% while maintaining ISO 8573‑1 Class 0 oil‑free air. Leading providers such as Quincy Compressor, Atlas Copco and Ingersoll Rand offer certified, high‑efficiency systems that reduce downtime, compliance risk, and total cost of ownership.
Elevara Begins Phase 2b Trial of ELV001 in Rheumatoid Arthritis
Elevara Medicines has dosed the first patient in its phase 2b START‑SYNERGY trial, testing the oral CDK4/6 inhibitor ELV001 in rheumatoid arthritis patients who have failed methotrexate and TNF inhibitors. The randomized, placebo‑controlled study will enroll about 180 participants across nine...
NHS to Offer Fezolinetant for Menopause‑related Hot Flushes and Night‑sweats
NICE has issued final draft guidance recommending fezolinetant 45 mg once daily for moderate to severe menopause‑related vasomotor symptoms when hormone replacement therapy is unsuitable. The recommendation enables the drug to be supplied through the NHS, providing a new non‑hormonal option...
Dr Klaas Zuideveld
TECregen, a biotech firm developing thymus‑rejuvenating biologics, announced Dr Klaas Zuideveld as its new chief executive officer. Zuideveld brings more than two decades of experience in pharmaceutical and biotech leadership, spanning translational strategy, clinical development, and global regulatory affairs. He has overseen...
Theolytics Awarded €8 Million Horizon Europe Grant to Fund Ovarian Cancer Study
Theolytics, an Oxford‑based biotech, secured an €8 million non‑dilutive Horizon Europe grant to fund its phase 2 OCTOPOD‑IV expansion trial of THEO‑260, a novel oncolytic therapy for advanced ovarian cancer. The grant, awarded after a rigorous review, will finance the phase 2a portion...
Bioxytran Reports Positive Phase 1b/2a Results for Antiviral ProLectin‑M
Bioxytran announced positive phase 1b/2a data for its oral antiviral ProLectin‑M in a randomized, double‑blind, placebo‑controlled trial of 39 mild‑to‑moderate COVID‑19 patients in India. The highest dose (16,800 mg/day) achieved viral clearance in 90% of participants by day 5 versus 20% on placebo,...
Verdiva Bio Completes Enrolment for Phase 2b Study of Oral GLP‑1 Candidate VRB‑101
Verdiva Bio announced that enrollment for its phase 2b EVOLVE‑2 trial of VRB‑101, a once‑weekly oral GLP‑1 peptide analog for weight loss, is complete with more than 200 participants across 22 U.S. sites. The double‑blind, placebo‑controlled study will assess safety, tolerability...
Katerina Leftheris
Enhanced Genomics announced the appointment of Katerina Leftheris to its board of directors, tapping her extensive medicinal chemistry and machine‑learning drug‑discovery experience. Leftheris most recently served as Chief Scientific Officer at Vilya, a company focused on oral macrocycle therapeutics, and...
Rebecca Simmons
Qureight announced that Rebecca Simmons has been appointed Chief Operating Officer. The move comes as the company seeks to scale its clinical development platform and broaden its market reach. Simmons joins Qureight after a 15‑year track record in pharmaceutical operations...
Strong Clinical Data for Breye Lead Asset Danegaptide
Breye Therapeutics presented early-phase data on its oral small‑molecule danegaptide for non‑proliferative diabetic retinopathy (NPDR). In a multi‑centre phase 1b study of 24 patients, the drug was well tolerated and achieved plasma concentrations within the target range. More than half of...
Connect More
Veeva Systems’ Aaron Bean outlines five connected engagement models for biopharma, from strategic account management to marketing‑centric approaches, to address mounting access challenges in the UK and Europe. He highlights that HCP accessibility in the UK is only 25% versus...
Patient-Centric Oncology Trials
Pharma companies are redesigning oncology trials to place patients at the center of study design, leveraging real‑world data and digital biomarkers. Adaptive protocols now allow dose adjustments and endpoint modifications based on individual responses. Collaborative platforms connect patients, investigators, and...
Thomas Farrell
NanoSyrinx, a synthetic‑biology firm developing nanosyringe platforms for intracellular delivery, announced Thomas J. Farrell as its new Chief Executive Officer and Director, succeeding founder Joe Healey. Farrell brings more than 25 years of biotherapeutics leadership, having founded two NASDAQ‑listed companies...
ENA Respiratory Begins Dosing in Phase 2 Study of INNA‑051 Nasal Spray
ENA Respiratory has initiated dosing in a Phase 2 clinical trial of its intranasal antiviral, INNA‑051. The study evaluates the spray’s ability to curb viral replication in the upper respiratory tract of adults presenting mild respiratory symptoms. Approximately 200 participants will...
True Colours
The article outlines the gold standard for spectroscopy in pharmaceutical labs, emphasizing that precise colour and turbidity measurements underpin brand integrity, product identification, and patient safety. It profiles six manufacturers—HunterLab, Shimadzu, PerkinElmer, Thermo Fisher Scientific, Agilent, and Mettler Toledo—detailing flagship...